脓毒症相关性血小板减少症的治疗进展并文献复习

Treatment progress and literature review of sepsis-associated thrombocytopenia

脓毒症是重症监护病房(ICU)中感染死亡的主要原因,血小板减少是其常见并发症。持续性血小板减少是危重症患者预后不良的标志。脓毒症相关性血小板减少症(SAT)涉及多种病理生理机制,在凝血和炎症反应中血小板起到了关键作用。血小板计数(PLT)不仅可以预测脓毒症患者预后,也可作为脓毒症患者的治疗靶点,提高脓毒症患者抢救成功率。现就血小板在脓毒症患者发病过程中的病理生理机制、预后、治疗等方面的作用进行文献复习。

Sepsis is the main cause of infection death in intensive care unit(ICU),and thrombocytopenia is a common complication.Persistent thrombocytopenia is a marker of poor prognosis in critically ill patients.Sepsisassociated thrombocytopenia(SAT)involves a variety of pathophysiological mechanisms,and platelets play a key role in coagulation and inflammatory response.Platelet count(PLT)can not only predict the prognosis of patients with sepsis,but also be used as a therapeutic target to improve the success rate of rescue in patients with sepsis.This article will review the pathophysiological mechanism,prognosis and treatment of platelets in septic patients.